Table 3

Dosing period and inhibitory effect of leflunomide in anaphylactic shock model

Antigen	Leflunomide	Dosing Period	Total IgE on Day 9	OVA-Specific IgE on Day 9	Histamine level on Day 10		No. Survived/Total
Antigen	Leflunomide	Dosing Period	Total IgE on Day 9	OVA-Specific IgE on Day 9	Before challenge	After challenge	No. Survived/Total
	mg/kg	days	μg/ml	U	μM
Expt. 1
			2.02 ± 0.61***	<0.5***	0.55 ± 0.14	0.43 ± 0.13***	5 /5
OVA	1% CMC	0–9	322.48 ± 88.10	22.17 ± 8.51	0.50 ± 0.19	30.38 ± 11.90	0 /5
OVA	2	0–3	24.68 ± 18.81***	1.12 ± 0.88***	0.56 ± 0.14	12.47 ± 8.96*	5 /6
OVA	2	0–6	0.50 ± 0.13***	<0.5***	0.47 ± 0.17	0.99 ± 0.56***	5 /6
OVA	2	0–9	0.38 ± 0.04***	<0.5***	0.76 ± 0.37	0.44 ± 0.19***	5 /5
OVA	2	3–9	1.56 ± 2.78***	<0.5***	0.47 ± 0.10	0.66 ± 0.57***	6 /6
OVA	2	6–9	44.84 ± 46.31***	1.37 ± 0.87***	0.62 ± 0.18	19.92 ± 6.77	2 /6
Expt. 2
			3.72 ± 2.42***	<0.5***	0.39 ± 0.20	0.28 ± 0.07***	6 /6
OVA	1% CMC	0–9	420.60 ± 194.00	24.69 ± 4.34	0.62 ± 0.16	46.55 ± 6.78	0 /5
OVA	2	0–9	0.45 ± 0.06***	<0.5***	0.42 ± 0.10*	0.30 ± 0.17***	6 /6
OVA	2	3–6	2.53 ± 2.93***	<0.5***	0.67 ± 0.23	2.80 ± 4.07***	6 /6
OVA	10	0–3	2.86 ± 1.20***	<0.5***	0.51 ± 0.20	0.53 ± 0.17***	2 /6

Values represents the mean ± S.D. When the OVA-specific IgE titer was below the limit of detection (0.5 U) in all animals per group, a provisional value of < 0.5 was used. When a value below the limit of detection was obtained in some animals per group, statistical analysis was performed using a provisional value of 0.5. Differences from the CMC control group were tested for significance by Welch’s t test (* P < .02; *** P < .001).